Tardive Dyskinesia Market Seen Growing 8.1% Through 2036 as New Therapies Target $4.4 Billion Base
Updated
Updated · PR Newswire · Jul 8
Tardive Dyskinesia Market Seen Growing 8.1% Through 2036 as New Therapies Target $4.4 Billion Base
1 articles · Updated · PR Newswire · Jul 8
Summary
$4.4 billion was the tardive dyskinesia market size across the seven major markets in 2025, and DelveInsight projects 8.1% annual growth from 2026 to 2036.
1.7 million prevalent cases in the 7MM in 2025, wider antipsychotic use, better diagnosis, aging populations and rising uptake of VMAT2 inhibitors are expected to expand the treated patient pool.
98% of the 2025 market sat in the United States, where approved VMAT2 inhibitors INGREZZA and AUSTEDO XR remain the standard of care despite underdiagnosis and side-effect limits.
Phase II candidate NBI-1065890 leads a relatively thin pipeline that also includes SOM3355, LY03015, ACP-271, SER-270 and TARDOXAL, with new launches expected to diversify a market still dominated by symptomatic therapies.